These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6145173)

  • 1. [Antipsychotic effects of caerulein on chronic schizophrenia].
    Moroharu T; Watanabe N; Ito M
    Seishin Shinkeigaku Zasshi; 1983; 85(9):611-5. PubMed ID: 6145173
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of caeruletide (883-S) in chronic schizophrenia].
    Kudo Y
    Seishin Shinkeigaku Zasshi; 1983; 85(11):797-801. PubMed ID: 6146148
    [No Abstract]   [Full Text] [Related]  

  • 3. Is cholecystokinin therapeutic in chronic schizophrenia?
    Boza RA; Rotondo DJ
    J Clin Psychiatry; 1985 Nov; 46(11):485-6. PubMed ID: 3902807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study.
    Lotstra F; Verbanck P; Mendlewicz J; Vanderhaeghen JJ
    Biol Psychiatry; 1984 Jun; 19(6):877-82. PubMed ID: 6378259
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacotherapy of chronic hospitalized schizophrenics: diagnosis and treatment.
    Ban TA; Guy W; Wilson WH
    Psychiatr J Univ Ott; 1984 Dec; 9(4):191-5. PubMed ID: 6151202
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of acute schizophrenia with sulforidazine].
    Sánchez E; Ning JL; Núñez H; Medina E
    Rev Neuropsiquiatr; 1975 Jun; 38(2):94-105. PubMed ID: 1839
    [No Abstract]   [Full Text] [Related]  

  • 7. An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity.
    Chouinard G; Turnier L
    Psychopharmacol Bull; 1986; 22(1):267-71. PubMed ID: 2873615
    [No Abstract]   [Full Text] [Related]  

  • 8. Kraepelinian schizophrenia: a subgroup of schizophrenia?
    Keefe RS; Mohs RC; Davidson M; Losonczy MF; Silverman JM; Lesser JC; Horvath TB; Davis KL
    Psychopharmacol Bull; 1988; 24(1):56-61. PubMed ID: 2898796
    [No Abstract]   [Full Text] [Related]  

  • 9. The first clinical study of BW-234U in schizophrenia.
    Davidson J; Miller R; Wingfield M; Zung W; Dren AT
    Psychopharmacol Bull; 1982 Oct; 18(4):173-6. PubMed ID: 6130560
    [No Abstract]   [Full Text] [Related]  

  • 10. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
    Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
    Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes in the eye movements of chronic schizophrenics as a result of treatment with a CCK-8-like drug (caerulein)].
    Sudo K; Koyama T; Ichikawa J; Yasuda M; Kazawa T
    Seishin Shinkeigaku Zasshi; 1983; 85(11):805-7. PubMed ID: 6677916
    [No Abstract]   [Full Text] [Related]  

  • 13. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 14. Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients.
    Rada RT; Donlon PT
    Psychosomatics; 1972; 13(6):373-6. PubMed ID: 4153002
    [No Abstract]   [Full Text] [Related]  

  • 15. [FDA phase II and phase III drug evaluation of antipsychotic agents].
    Yagi K
    Seishin Shinkeigaku Zasshi; 1990; 92(9):584-92. PubMed ID: 1980369
    [No Abstract]   [Full Text] [Related]  

  • 16. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
    Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
    Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling acute and chronic schizophrenia. Drug therapy today.
    Rodman MJ
    RN; 1978 Apr; 41(4):75-83. PubMed ID: 24888
    [No Abstract]   [Full Text] [Related]  

  • 18. Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia.
    Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM
    Psychopharmacology (Berl); 2001 Sep; 157(3):284-91. PubMed ID: 11605084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.
    Tan YL; Zhou DF; Cao LY; Zou YZ; Zhang XY
    Neurosci Lett; 2005 Jul 1-8; 382(1-2):27-32. PubMed ID: 15911116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
    Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.